Stocktoria

Vivani Medical, Inc. VANI

Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
1/9
Piotroski F — financial health
-14.41
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$0-$26.6M-$25.5M$15.7M
2024$0-$23.5M-$21.3M$17.6M
2023-$25.7M-$24.6M$20.8M
2022-$13.9M-$19.1M$44.3M
2021-$12.8M$130,000-$11.5M$2.5M
2020-$14.9M$500,000-$17.2M$1.9M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Williams Greggdirector2026-06-15Buy1,587,301$1.26
Williams Greggdirector2026-05-15Buy1,587,301$1.26
Williams Greggdirector2026-04-15Buy1,587,301$1.26
Williams Greggdirector2026-03-15Buy1,310,680$1.03
Williams Greggdirector2026-03-15Buy264,551$1.26
Williams Greggdirector2026-02-15Buy1,601,941$1.03
Williams Greggdirector2026-02-15Buy264,551$1.26

Why these scores methodology →

Piotroski F-score: 1/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -14.41 (distress)

  • Working capital / assets 0.287
  • Retained earnings / assets -3.771
  • EBIT / assets -0.7
  • Equity / liabilities 0.665

Source: SEC EDGAR filings · CIK 0001266806 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.